News Archive

EUSA Pharma announces
$30 million Debt Facility with
Merrill Lynch Capital

12 December 2007.
EUSA Pharma announced that it has entered into a $30 million debt facility offered by Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc, and its affiliates.

The funds raised will be used to continue the acceleration of EUSA’s growth, to expand the
Company’s portfolio and to further enhance EUSA’s marketing capabilities for its key products,
Erwinase®, Collatamp® G and Rapydan®, which will be launched imminently following the recent successful completion of the European Mutual Recognition Procedure. Since its establishment in 2006, EUSA has made three significant acquisitions, building a portfolio of six products on the market and several others in late-stage development.

“The provision of the debt facility announced today ensures that we are well positioned to accelerate
our growth plans and continue to progress towards our goal of becoming a leading transatlantic
specialty pharmaceutical company,” said Bryan Morton, Chief Executive of EUSA Pharma. “We are delighted to be entering into this arrangement with Merrill Lynch Capital. Their confidence in EUSA is further validation of our strategy to become a leading player in our field.”

Download PDF
of transcript (48KB)